CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Nov. 6, 2020—Oxford Gene Technology has expanded its SureSeq range of next-generation sequencing panels to include a comprehensive myeloid panel and a breast and ovarian cancer panel that incorporate copy number variation detection.
The SureSeq Pan-Myeloid panel includes 70 key genes implicated in a wide range of myeloid disorders, including acute myeloid leukemia, myeloproliferative neoplasms, and myelodysplastic syndrome. The panel provides excellent coverage uniformity to detect clinically relevant single nucleotide variants and indels down to one percent variant allele frequency. CEBPA, JAK2, CALR, MPL, and other genes are included in the panel, and regions containing hard-to-detect structural variants such as FLT3-ITDs and KMT2A-PTDs are covered.